Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 4/2010

01-12-2010 | NON-THEMATIC REVIEW

Regulatory T cells and breast cancer: implications for immunopathogenesis

Authors: Maria Angelica Ehara Watanabe, Julie Massayo Maeda Oda, Marla Karine Amarante, Julio Cesar Voltarelli

Published in: Cancer and Metastasis Reviews | Issue 4/2010

Login to get access

Abstract

Current understanding of the role of several cancer risk factors is more comprehensive, as reported for a number of sites, including the brain, colon, breasts, and ovaries. Despite such advances, the incidence of breast cancer continues to increase worldwide. Signals from the microenviroment have a profound influence on the maintenance or progression cancers. Although T cells present the most important immunological response in tumor growth in the early stages of cancer, they become suppressive CD4+ and CD8+ regulatory T cells (Tregs) after chronic stimulation and interactions with tumor cells, thus promoting rather than inhibiting cancer development and progression. Tregs have an important marker protein which is FoxP3, though it does not necessarily confer a Treg phenotype when expressed in CD4+ T lymphocytes. High Treg levels have been reported in peripheral blood, lymph nodes, and tumor specimens from patients with different types of cancer. The precise mechanisms by which Tregs suppress immune cell functions remain unclear, and there are reports of both direct inhibition through cell–cell contact and indirect inhibition through the secretion of anti-inflammatory mediators such as interleukin. In this review, we present the molecular and immunological aspects of Treg cells in the metastasis of breast cancer.
Literature
1.
Chu, D., & Lu, J. (2008). Novel therapies in breast cancer: What is new from ASCO 2008. Journal of Hematology Oncology, 1, 1–16.CrossRef
2.
Kásler, M., Polgár, C., & Fodor, J. (2009). Current status of treatment for early-stage invasive breast cancer. Orvosi Hetilap, 150, 1013–1021.CrossRefPubMed
3.
Benz, C. C. (2008). Impact of aging on the biology of breast cancer. Impact of aging on the biology of breast cancer. Critical Reviews in Oncology/Hematology, 66(1), 65–74.CrossRefPubMed
4.
Lacroix, M., Toillon, R. A., & Leclercq, G. (2004). Stable ‘portrait’ of breast tumors during progression: Data from biology, pathology and genetics. Endocrine-Related Cancer, 11, 497–522.CrossRefPubMed
5.
Rakha, E. A., El-Sayed, M. E., Reis-Filho, J., & Ellis, I. O. (2009). Patho-biological aspects of basal-like breast cancer. Breast Cancer Research and Treatment, 113, 411–422.CrossRefPubMed
6.
Beckmann, M. W., Niederacher, D., Schnürch, H. G., Gusterson, B. A., & Bender, H. G. (1997). Multistep carcinogenesis of breast cancer and tumour heterogeneity. Journal of Molecular Medicine, 75, 429–439.CrossRefPubMed
7.
Perou, C. M., Sorlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., et al. (2000). Molecular portraits of human breast tumours. Nature, 406, 747–752.CrossRefPubMed
8.
Sorlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., et al. (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of USA, 98, 10869–10874.CrossRef
9.
Sorlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., et al. (2003). Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of USA, 100, 8418–8423.CrossRef
10.
Bertucci, F., Houlgatte, R., Benziane, A., Granjeaud, S., Adélaïde, J., Tagett, R., et al. (2000). Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Human Molecular Genetics, 9, 2981–2991.CrossRefPubMed
11.
Bergamaschi, A., Kim, Y. H., Wang, P., Sorlie, T., Hernandez-Boussard, T., & Lonning, P. E. (2006). Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes, Chromosomes & Cancer, 45, 1033–1040.CrossRef
12.
Chin, K., DeVries, S., Fridlyand, J., Spellman, P. T., Roydasgupta, R., & Kuo, W. L. (2006). Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell, 10, 529–541.CrossRefPubMed
13.
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., et al. (2006). A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell, 10, 515–527.CrossRefPubMed
14.
Aoki, M. N., da Silva do Amaral Herrera, A. C., Amarante, M. K., do Val Carneiro, J. L., Fungaro, M. H., & Watanabe, M. A. (2009). CCR5 and p53 codon 72 gene polymorphisms: Implications in breast cancer development. International Journal of Molecular Medicine, 23, 429–435.PubMed
15.
Hori, S., Nomura, T., & Sakaguchi, S. (2003). Control of regulatory T cell development by the transcription factor FoxP3. Science, 299, 1057–1061.CrossRefPubMed
16.
Bernardes, S. S., Borges, I. K., Lima, J. E., de Azevedo Oliveira Milanez, P., Costa, I. C., Felipe, I., et al. (2010). Involvement of regulatory T cells in HIV immunopathogenesis. Current HIV Research, 8, 340–346.CrossRefPubMed
17.
Rosenberg, S. A. (2001). Progress in human tumour immunology and immunotherapy. Nature, 411, 380–384.CrossRefPubMed
18.
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004). The immunobiology of cancer immunosurveillance and immunoediting. Immunity, 21, 137–148.CrossRefPubMed
19.
Dougan, M., & Dranoff, G. (2009). The immune response to tumors. Current Protocols in Immunology. Chapter 20, Unit 20.11.
20.
Amarante, M. K., & Watanabe, M. A. E. (2009). The possible involvement of virus in breast cancer. Journal of Cancer Research and Clinical Oncology, 135(3), 329–337.CrossRefPubMed
21.
Standish, L. J., Sweet, E. S., Novack, J., Wenner, C. A., Bridge, C., Nelson, A., et al. (2008). Breast cancer and the immune system. Journal of the Society for Integrative Oncology, 6, 158–168.PubMed
22.
Kazbariene, B. (2009). Tumor and immunity. Medicina, 45, 162–167.PubMed
23.
Tan, T. T., & Coussens, L. M. (2007). Humoral immunity, inflammation and cancer. Current Opinion in Immunology, 19, 209–216.CrossRefPubMed
24.
DeNardo, D. G., & Coussens, L. M. (2007). Inflammation and breast cancer. Balancing immune response: Crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Research, 9, 212.CrossRefPubMed
25.
Wang, R. F. (2008). CD8+ regulatory T cells, their suppressive mechanisms, and regulation in cancer. Human Immunology, 69, 811–814.CrossRefPubMed
26.
Sakaguchi, S., Wing, K., & Miyara, M. (2007). Regulatory T cells—A brief history and perspective. European Journal of Immunology, 37(Suppl 1), S116–S123.CrossRefPubMed
27.
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995). Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. Journal of Immunology, 155(3), 1151–1164.
28.
Shevach, E. M. (2002). CD4−CD25− suppressor T cells: More questions than answers. Nature Reviews. Immunology, 2, 389–400.PubMed
29.
Wood, K. J., & Sakaguchi, S. (2003). Regulatory lymphocytes: Regulatory T cells in transplantation tolerance. Nature Review Immunology, 3, 199–210.CrossRef
30.
Maloy, K. J., & Powrie, F. (2001). Regulatory T cells in the control of immune pathology. Nature Immunology, 2, 816–822.CrossRefPubMed
31.
32.
Feuerer, M., Hill, J. A., Mathis, M., & Benoist, C. (2009). FoxP3+ regulatory T cells: Differentiation, specification, subphenotypes. Nature Immunolgy, 10, 689–695.CrossRef
33.
Curti, A., Pandolfi, S., Valzasina, B., Aluigi, M., Isidori, A., Ferri, E., et al. (2007). Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25S into CD25R T regulatory cells. Blood, 109, 2871–2877.PubMed
34.
Thornton, A. M., & Shevach, E. M. (1998). CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. The Journal of Experimental Medicine, 188, 287–296.CrossRefPubMed
35.
Wang, H. Y., Peng, G., Guo, Z., Shevach, E. M., & Wang, R. F. (2005). Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. Journal of Immunology, 174, 2661–2670.
36.
Roncarolo, M. G., Gregori, S., Battaglia, M., Bacchetta, R., Fleischhauer, K., & Levings, M. K. (2006). Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunological Reviews, 212, 28–50.CrossRefPubMed
37.
Weiner, H. L. (2001). Induction and mechanism of action of transforming growth factor beta-secreting Th3 regulatory cells. Immunological Reviews, 182, 207–214.CrossRefPubMed
38.
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003). FoxP3 programs the development and function of CD4+CD25 regulatory T cells. Nature Immunology, 4, 330–336.CrossRefPubMed
39.
Bacchetta, R., Passerini, L., Gambineri, E., Daí, M., Allan, S. E., Perroni, L., et al. (2006). Defective regulatory and effector T cell functions in patients with FoxP3 mutations. The Journal of Clinical Investigation, 116, 1713–1722.CrossRefPubMed
40.
Gavin, M. A., Torgerson, T. R., Houston, E., DeRoos, P., Ho, W. Y., Stray-Pedersen, A., et al. (2006). Single-cell analysis of normal and FOXP3-mutant human T cells: FoxP3 expression without regulatory T cell development. Proceedings of the National Academy of Sciences of the USA, 103, 6659–6664.CrossRefPubMed
41.
Roncador, G., Brown, P. J., Maestre, L., Hue, S., Martínez-Torrecuadrada, J. L., Ling, K. L., et al. (2005). Analysis of FoxP3 protein expression in human CD4(+)CD25(+) regulatory T cells at the single-cell level. European Journal of Immunology, 35, 1681–1691.CrossRefPubMed
42.
Li, B., Saouaf, S. J., Samanta, A., Shen, Y., Hancock, W. W., & Greene, M. I. (2007). Biochemistry and therapeutic implications of mechanisms involved in FoxP3 activity in immune suppression. Current Opinion in Immunology, 19, 583–588.CrossRefPubMed
43.
Wu, Y., Borde, M., Heissmeyer, V., Feuerer, M., Lapan, A. D., Stroud, J. C., et al. (2006). FoxP3 controls regulatory T cell function through cooperation with NFAT. Cell, 126, 375–387.CrossRefPubMed
44.
Cruvinel, W. M., Mesquita, D., Jr., Araújo, J. A. P., Salmazi, K. C., Kállas, E. G., Andrade, L. E. C., et al. (2008). Natural regulatory T cells in rheumatic diseases. Revista Brasileira de Reumatologia, 48, 342–355.CrossRef
45.
Lin, H., Sun, X. F., Zhen, Z. J., Xia, Y., Ling, J. Y., Huang, H. Q., et al. (2009). Correlation between peripheral blood CD4+CD25highCD127low regulatory T cell and clinical characteristics of patients with non-Hodgkin’s lymphoma. Ai Zheng, 28(11), 1186–1192.PubMed
46.
Whiteside, T. L. (2006). Immune suppression in cancer: Effects on immune cells, mechanisms and future therapeutic intervention. Seminars in Cancer Biology, 16(1), 3–15.CrossRefPubMed
47.
Mansfield, A. S., Heikkila, P. S., Vaara, A. T., von Smitten, K. A., Vakkila, J. M., & Leidenius, M. H. (2009). Simultaneous FoxP3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer, 9, 231.CrossRefPubMed
48.
Zhou, L., Lopes, J. E., Chong, M. M. W., Ivanov, I. I., Min, R., Victora, G. D., et al. (2008). TGF-β-induced FoxP3 inhibits TH17 cell differentiation by antagonizing RORγt function. Nature, 453, 236–240.CrossRefPubMed
49.
Voo, K. S., Wang, Y. H., Santori, F. R., Boggiano, C., Wang, Y. H., Arima, K., et al. (2009). Identification of IL-17-producing FoxP3+ regulatory T cells in humans. Proceedings of the National Academy of Sciences of USA, 106, 4793–4798.CrossRef
50.
Beyer, M., Kochanek, M., Giese, T., Endl, E., Weihrauch, M. R., Knolle, P. A., et al. (2006). In vivo peripheral expansion of naive CD4+CD25highFoxP3+ regulatory T cells in patients with multiple myeloma. Blood, 107, 3940–3949.CrossRefPubMed
51.
Wang, H. Y., & Wang, R. F. (2007). Regulatory T cells and cancer. Current Opinion in Immunology, 19, 217–223.CrossRefPubMed
52.
Liu, Z., Kim, J. H., Falo, L. D., Jr., & You, Z. (2009). Tumor regulatory T cells potently abrogate antitumor immunity. Journal of Immunology, 182, 6160–6167.CrossRef
53.
Konwar, R., Chaudhary, P., Kumar, S., Mishra, D., Chattopadhyay, N., & Bid, H. K. (2009). Breast cancer risks associated with polymorphisms of IL-1RN and IL-4 gene in Indian women. Oncology Research, 17, 367–372.CrossRefPubMed
54.
Zhou, X., Bailey-Bucktrout, S., Jeker, L. T., & Bluestone, J. A. (2009). Plasticity of CD4(+) FoxP3(+) T cells. Current Opinion in Immunology, 21, 281–285.CrossRefPubMed
55.
Kosmaczewska, A., Ciszak, L., Potoczek, S., & Frydecka, I. (2008). The significance of Treg cells in defective tumor immunity. Archivum Immunologiae et Therapie Experimentalis, 56, 181–191.CrossRef
56.
Gupta, S., Joshi, K., Wig, J. D., & Arora, S. K. (2007). Intratumoral FoxP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis. Acta Oncológica, 46, 792–797.CrossRefPubMed
57.
Karanikas, V., Speletas, M., Zamanakou, M., Kalala, F., Loules, G., Kerenidi, T., et al. (2008). FoxP3 expression in human cancer cells. Journal of Translational Medicine, 6, 19.CrossRefPubMed
58.
Liu, L., Wu, G., Yao, J. X., Liu, L., Wu, G., Yao, J. X., et al. (2008). CD4+CD25high regulatory cells in peripheral blood of cancer patients. Neuro Endocrinology Letters, 29, 240–245.PubMed
59.
Bates, G. J., Fox, S. B., Han, C., Leek, R. D., Garcia, J. F., Harris, A. L., et al. (2006). Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. Journal of Clinical Oncology, 24, 5373–5380.CrossRefPubMed
60.
Liu, Y., & Zheng, P. (2007). FoxP3 and breast cancer: Implications for therapy and diagnosis. Pharmacogenomics, 8, 1485–1487.CrossRefPubMed
61.
Zuo, T., Wang, L., Morrison, C., Chang, X., Zhang, H., Li, W., et al. (2007). FoxP3 is an X-linked breast cancer suppressor gene and an important repressor of HER-2/ErbB2 oncogene. Cell, 129, 1275–1286.CrossRefPubMed
62.
Ohara, M., Yamaguchi, Y., Matsuura, K., Murakami, S., Arihiro, K., & Okada, M. (2009). Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer. Cancer Immunology Immunotherapy: CII, 58, 441–447.CrossRef
63.
Ladoire, S., Arnould, L., Mignot, G., Coudert, B., Rébé, C., Chalmin, F., et al. (2010). Presence of FoxP3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment, doi:10.​1007/​s10549-010-0831-1
64.
Selenko-Gebauer, N., Majdic, O., Szekeres, A., Höfler, G., Guthann, E., Korthäuer, U., et al. (2003). B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. Journal of Immunology, 170, 3637–3644.
65.
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002). Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proceedings of the National Academy of Sciences of the USA, 99, 12293–12297.CrossRefPubMed
66.
Ghebeh, H., Barhoush, E., Tulbah, A., Elkum, N., Al-Tweigeri, T., & Dermime, S. (2008). FoxP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy. BMC Cancer, 23, 8–57.
67.
Berger, C. L., Tigelaar, R., Cohen, J., Mariwalla, K., Trinh, J., Wang, N., et al. (2005). Cutaneous T cell lymphoma: Malignant proliferation of T regulatory cells. Blood, 105, 1640–1647.CrossRefPubMed
68.
Karube, K., Ohshima, K., Tsuchiya, T., Yamaguchi, T., Kawano, R., Suzumiya, J., et al. (2004). Expression of FoxP3, a key molecule in CD4+CD25+ regulatory T cells, in adult T cell leukaemia/lymphoma cells. British Journal Haematology, 126, 81–84.CrossRef
69.
Liyanage, U. K., Moore, T. T., Joo, H. G., Tanaka, Y., Herrmann, V., Doherty, G., et al. (2002). Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. Journal of Immunology, 169, 2756–2761.
70.
Perez, S. A., Karamouzis, M. V., Skarlos, D. V., Ardavanis, A., Sotiriadou, N. N., Iliopoulou, E. G., et al. (2007). CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients. Clinical Cancer Research, 13, 2714–2721.CrossRefPubMed
71.
Wolf, A. M., Wolf, D., Steurer, M., Gastl, G., Gunsilius, E., Grubeck-Loebenstein, B., et al. (2003). Increase of regulatory T cells in the peripheral blood of cancer patients. Clinical Cancer Research, 9(2), 606–612.PubMed
72.
Bi, Y., Wei, L., Mao, H. T., Zhang, L., & Zuo, W. S. (2008). Expressions of Fas, CTLA-4 and RhoBTB2 genes in breast carcinoma and their relationship with clinicopathological factors. Zhonghua ZhongLiu Za Zhi, 30, 749–753.
73.
Jaberipour, M., Habibagahi, M., Hosseini, A., Habibabad, S. R., Talei, A., & Ghaderi, A. (2010). Increased CTLA-4 and FOXP3 transcripts in peripheral blood mononuclear cells of patients with breast cancer. Pathology Oncology Research, doi:10.​1007/​s12253-010-9256-8
74.
Raskin, L., Rennert, G., & Gruber, S. B. (2009). FoxP3 germline polymorphisms are not associated with risk of breast cancer. Cancer Genetics and Cytogenetics, 190, 40–42.CrossRefPubMed
75.
Fidler, I. J. (2003). The pathogenesis of cancer metastasis: The ‘seed and soil’ hypothesis revisited. Nature Reviews. Cancer, 3, 453–458.CrossRefPubMed
76.
Gupta, G. P., & Massagué, J. (2006). Cancer metastasis: Building a framework. Cell, 127, 679–695.CrossRefPubMed
77.
Audia, S., Nicolas, A., Cathelin, D., Larmonier, N., Ferrand, C., Foucher, P., et al. (2007). Increase of CD4+ CD25++ regulatory T cells in the peripheral blood of patients with metastatic carcinoma: A phase I clinical trial using cyclophosphamide and immunotherapy to eliminate CD4+CD25+ T lymphocytes. Clinical and Experimental Immunology, 150(3), 523–530.CrossRefPubMed
78.
Rech, A. J., Mick, R., Kaplan, D. E., Chang, K. M., Domchek, S. M., & Vonderheide, R. H. (2010). Homeostasis of peripheral FoxP3(+) CD4 (+) regulatory T cells in patients with early and late stage breast cancer. Cancer Immunology, Immunotherapy, 59(4), 599–607.CrossRefPubMed
79.
Aruga, T., Suzuki, E., Saji, S., Horiguchi, S., Horiguchi, K., Sekine, S., et al. (2009). A low number of tumor-infiltrating FOXP3-positive cells during primary systemic chemotherapy correlates with favorable anti-tumor response in patients with breast cancer. Oncology Reports, 22, 273–278.PubMed
80.
Merlo, A., Casalini, P., Carcangiu, M. L., Malventano, C., Triulzi, T., Mènard, S., et al. (2009). FoxP3 expression and overall survival in breast cancer. Journal of Clinical Oncology, 27, 1746–1752.CrossRefPubMed
81.
Carneiro, J. L. V., Nixdorf, S. L., Mantovani, M. S., da Silva do Amaral Herrera, A. C., Aoki, M. N., Amarante, M. K., et al. (2009). Plasma malondialdehyde levels and CXCR4 expression in peripheral blood cells of breast cancer patients. Journal of Cancer Research and Clinical Oncology, 135, 997–1004.CrossRef
82.
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., et al. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature, 410(6824), 50–56.CrossRefPubMed
83.
Shimizu, Y., Dobashi, K., Imai, H., Sunaga, N., Ono, A., Sano, T., et al. (2009). CXCR4+FOXP3+CD25+ lymphocytes accumulate in CXCL12-expressing malignant pleural mesothelioma. International Journal of Immunopathology and Pharmacology, 22, 43–51.PubMed
84.
Ishida, T., & Ueda, R. (2006). CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Science, 97(11), 1139–1146.CrossRefPubMed
85.
Mougiakakos, D., Choudhury, A., Lladser, A., Kiessling, R., & Johansson, C. C. (2010). Regulatory T cells in cancer. Advances in Cancer Research, 107, 57–117.CrossRefPubMed
86.
Xu, L., Xu, W., Qiu, S., & Xiong, S. (2010). Enrichment of CCR6(+)Foxp3(+) regulatory T cells in the tumor mass correlates with impaired CD8(+) T cell function and poor prognosis of breast cancer. Clinical Immunology, 135, 466–475.CrossRefPubMed
87.
Tannock, I. F., Hill, R. P., Bristow, R. G., & Harrington, L. (2005). The basic science of oncology. New York: McGraw-Hill.
88.
Nguyen, D. X., & Massagué, J. (2007). Genetic determinants of cancer metastasis. Nature Reviews Genetics, 8, 341–352.CrossRefPubMed
89.
Alam, S. M., Clark, J. S., George, W. D., & Campbell, A. M. (1993). Altered lymphocyte populations in tumour invaded nodes of breast cancer patients. Immunology Letters, 35(3), 229–234.CrossRefPubMed
90.
Nakamura, R., Sakakibara, M., Nagashima, T., Sangai, T., Arai, M., Fujimori, T., et al. (2009). Accumulation of regulatory T cells in sentinel lymph nodes is a prognostic predictor in patients with node-negative breast cancer. European Journal of Cancer, 45, 2123–2131.CrossRefPubMed
91.
Matsuura, K., Yamaguchi, Y., Osaki, A., Ohara, M., Okita, R., Emi, A., et al. (2009). FoxP3 expression of micrometastasis-positive sentinel nodes in breast cancer patients. Oncology Reports, 22(5), 1181–1187.CrossRefPubMed
92.
Akhurst, R. J., & Derynck, R. (2001). TGF-beta signalling in cancer—A double-edged sword. Trends in Cell Biology, 11, S44–S51.PubMed
93.
94.
Pollard, J. W. (2004). Tumour-educated macrophages promote tumor progression and metastasis. Nature Reviews. Cancer, 4, 71–78.CrossRefPubMed
95.
Wels, J., Kaplan, R. N., Rafii, S., & Lyden, D. (2008). Migratory neighbors and distant invaders: Tumor-associated niche cells. Genes & Development, 22, 559–574.CrossRef
96.
Gobert, M., Treilleux, I., Bendriss-Vermare, N., Bachelot, T., Goddard-Leon, S., Arfi, V., et al. (2009). Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Research, 69(5), 2000–2009.CrossRefPubMed
97.
Zheng, Y., & Rudensky, A. Y. (2007). Foxp3 in control of the regulatory T cell lineage. Nature Immunology, 8, 457–462.CrossRefPubMed
98.
Kodama, J., Hasengaowa, Kusumoto, T., Seki, N., Matsuo, T., Ojima, Y., et al. (2007). Association of CXCR4 and CCR7 chemokine receptorexpression and lymph node metastasis in human cervical cancer. Annals of Oncology, 18, 70–76.CrossRefPubMed
99.
Pitkin, L., Luangdilok, S., Corbishley, C., Wilson, P. O., Dalton, P., Bray, D., et al. (2007). Expression of CC chemokine receptor 7 in tonsillar cancer predicts cervical nodal metastasis, systemic relapse and survival. British Journal of Cancer, 97, 670–677.CrossRefPubMed
100.
Lu, H. (2009). FoxP3 expression and prognosis: Role of both the tumor and T cells. Journal of Clinical Oncology, 27(11), 1735–1736.CrossRefPubMed
Metadata
Title
Regulatory T cells and breast cancer: implications for immunopathogenesis
Authors
Maria Angelica Ehara Watanabe
Julie Massayo Maeda Oda
Marla Karine Amarante
Julio Cesar Voltarelli
Publication date
01-12-2010
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 4/2010
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-010-9247-y

Other articles of this Issue 4/2010

Cancer and Metastasis Reviews 4/2010 Go to the issue

NON-THEMATIC REVIEW

Perspectives on the mesenchymal origin of metastatic cancer

NON-THEMATIC REVIEW

Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials

NON-THEMATIC REVIEW

Obesity and breast cancer: status of leptin and adiponectin in pathological processes

NON-THEMATIC REVIEW

DNA methylation or histone modification status in metastasis and angiogenesis-related genes: a new hypothesis on usage of DNMT inhibitors and S-adenosylmethionine for genome stability

Erratum

Erratum to: microRNAs and lung cancer: tumors and 22-mers

NON-THEMATIC REVIEW

CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits